Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Deals
Features
News
Region
Sectors
Size

Healthcare

SpyGlass observes $27.5m
The eye disease device developer has raised series B funding to advance research originating from University of Colorado's s Sue Anschutz-Rodgers Eye Center.
Lexeo stacks up $85m
Weill Cornell Medicine‘s monogenic diseases therapy developer Lexeo Therapeutics has made its public debut with $85m in series A financing.
LifeMine Therapeutics lands $50m
LifeMine’s chairman and co-founder Rick Klausner has co-led a round that included multiple corporates and pushed the overall equity to $120m.
Daily deal net: January 12, 2021
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Neural Galaxy detects pre-series A cash
The brain disease treatment developer was founded in 2019 on the back of more than a decade’s collaborative research from MIT and Harvard.
Carisma motivates investors for $47m series B
IP Group was among the investors for UPenn-founded cancer immunotherapy developer Carisma Therapeutics, which has now raised nearly $109m altogether.
Werewolf wins over UPMC for series B
UPMC Enterprise has returned for a $72m series B round raised by Werewolf Therapeutics, which is now set to advance two lead assets through phase 1 trials.
Dice Molecules determines series C investors
Osage University Partners has contributed to an $80m round for Dice Molecules, which is advancing Stanford University research and is also backed by Sanofi and Alexandria.

Other News

Daily deal net: January 8, 2021
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Neuros Medical implants $38.5m
CWRU‘s pain neurostimulation spinout has secured series BB funding ahead of a 180-patient trial.
UC Riverside anchors life sciences incubator
Biopolymer material decontamination company Karamedica and genomic sequencing provider Murrieta Genomics have both joined UC Riverside's newly-launched Life Sciences Incubator.
Investors hook up Hinge Health with $300m
IP Group portfolio company Hinge Health has pushed its valuation to $3bn following a $300m series D round co-led by Coatue Management and Tiger Global.
IconOVir Bio conducts $77m series A
The oncolytic virus therapy-based cancer drug developer is based on research at Salk Institute and has raised $77m in its series A round.
Daily deal net: January 5, 2021
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Editor's Picks

When worlds collide – CVC interest in spinouts
Steady is the assessment that comes to mind, rather than remarkable, when probing the year-on-year direction of corporate venture capital investment in university spinouts.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Otsuka takes up Veryan’s acquisition offer
ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.
Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
test reg

Login